129 related articles for article (PubMed ID: 37960879)
1. Acute infusion-related reactions in pediatric patients receiving etoposide at a tertiary cancer center.
McBride P; Degar B
J Oncol Pharm Pract; 2024 Jan; 30(1):197-200. PubMed ID: 37960879
[TBL] [Abstract][Full Text] [Related]
2. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease.
Hudson MM; Weinstein HJ; Donaldson SS; Greenwald C; Kun L; Tarbell NJ; Humphrey WA; Rupp C; Marina NM; Wilimas J
J Clin Oncol; 1993 Jun; 11(6):1080-4. PubMed ID: 8501494
[TBL] [Abstract][Full Text] [Related]
3. Risks and mitigation strategies to prevent etoposide infusion-related reactions in children.
Tillman EM; Suppes SL; Miles N; Duty AM; Kelley KL; Goldman JL
Pharmacotherapy; 2021 Aug; 41(8):700-706. PubMed ID: 34129705
[TBL] [Abstract][Full Text] [Related]
4. Etoposide and etoposide phosphate hypersensitivity in children: Incidence, risk factors, and prevention strategies.
Stockton WM; Nguyen T; Zhang L; Dowling TC
J Oncol Pharm Pract; 2020 Mar; 26(2):397-405. PubMed ID: 31315549
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.
Dorr RT; Briggs A; Kintzel P; Meyers R; Chow HH; List A
Bone Marrow Transplant; 2003 Apr; 31(8):643-9. PubMed ID: 12692603
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
7. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity.
Collier K; Schink C; Young AM; How K; Seckl M; Savage P
J Oncol Pharm Pract; 2008 Mar; 14(1):51-5. PubMed ID: 18337441
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of etoposide phosphate plus paclitaxel.
Brooks DJ; Alberts DS
Semin Oncol; 1996 Dec; 23(6 Suppl 13):30-3. PubMed ID: 8996573
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of clinical features and treatment outcomes of children with Hodgkin's Lymphoma treated with different chemotherapy protocols at a tertiary care center in Pakistan.
Mehreen A; Wali RM; Sindhu II; Asad M; Ria S
J Pak Med Assoc; 2019 Sep; 69(9):1266-1272. PubMed ID: 31511710
[TBL] [Abstract][Full Text] [Related]
11. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
12. Infusion of etoposide and vincristine in non-Hodgkin's lymphoma.
Jackson DV; Powell BL; Cruz JM; Spurr CL; Muss HB
Sel Cancer Ther; 1989; 5(3):129-36. PubMed ID: 2682876
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
14. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.
Santana VM; Schell MJ; Williams R; Bowman LC; Thompson EI; Brenner MK; Mirro J
Bone Marrow Transplant; 1992 Nov; 10(5):457-62. PubMed ID: 1464010
[TBL] [Abstract][Full Text] [Related]
15. Association between in-line filtration and Type I hypersensitivity reactions in pediatric oncology patients receiving intravenous etoposide.
Ronsley R; Jacques L; Potts JE; Clement K; Dix DB; Mahon P
Pediatr Hematol Oncol; 2021 Apr; 38(3):208-215. PubMed ID: 33150845
[TBL] [Abstract][Full Text] [Related]
16. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
17. Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity.
Brooks JP; Azmy V; Thompson A; Luon D; Prozora SD; Price C; Hsu FI
J Oncol Pharm Pract; 2020 Jan; 26(1):228-231. PubMed ID: 30885040
[TBL] [Abstract][Full Text] [Related]
18. A pediatric desensitization protocol for etoposide.
Martinez N; Miyasaki A; Roh L; Koole W; Fernandez KS
Am J Health Syst Pharm; 2020 Feb; 77(4):277-281. PubMed ID: 32031209
[TBL] [Abstract][Full Text] [Related]
19. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
